NCT07022483
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion moved earlier from Mar 23, 2032 to Feb 26, 2030 Show 5 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria shortened, about 8 words
- Trial sites expanded: 75 → 86 locations
- Secondary endpoints: details revised at 1 of 1 entry
- Study title expanded, about 4 words
- Minor Trial sites expanded: 61 → 75 locationsv7
- Minor Trial sites expanded: 40 → 61 locationsv6
- Minor Study sites: 17 to 40v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 17
- Start date changed from estimate of Oct 31, 2025 to Sep 30, 2025
Show 2 earlier versionsHide 2 earlier versions
- Notable Eligibility criteria expanded, about 22 wordsv3
- Notable Start date: Aug 25, 2025 to Oct 31, 2025v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Participants will receive T-DXd 5.4 mg/kg intravenously (IV) once every 3 weeks (Q3W) with or without \[optional\] radiotherapy
Participants will receive carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W, or AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W with or without \[optional\] radiotherapy or chemoradiotherapy (EBRT plus cisplatin \[as radiosensitizer\] 50 mg/m2
Drugs: Trastuzumab Deruxtecan, Chemotherapy
Sites
86 sites in 15 countries
China 16, Japan 15, United States 14, Italy 7, Argentina 6, Spain 6, Poland 4, Taiwan 4, Chile 3, France 3, South Korea 3, Germany 2, Greece 1, Israel 1, Portugal 1